Structure Therapeutics (NASDAQ:GPCR) Now Covered by HC Wainwright

Research analysts at HC Wainwright began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $80.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 140.60% from the stock’s current price.

Several other analysts have also recently issued reports on the stock. Morgan Stanley started coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, JMP Securities reduced their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of “Buy” and an average target price of $85.67.

Structure Therapeutics Stock Performance

GPCR stock opened at $33.25 on Wednesday. The stock has a market capitalization of $1.90 billion, a P/E ratio of -44.93 and a beta of -3.41. Structure Therapeutics has a one year low of $26.61 and a one year high of $66.38. The company has a 50 day moving average price of $37.83 and a two-hundred day moving average price of $39.42.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP lifted its position in shares of Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after acquiring an additional 221,851 shares in the last quarter. FMR LLC increased its stake in shares of Structure Therapeutics by 6.7% during the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Structure Therapeutics by 18.0% during the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares during the last quarter. Driehaus Capital Management LLC increased its stake in shares of Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after purchasing an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in Structure Therapeutics by 6.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after buying an additional 150,000 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.